Year All20242023202220212020201920182017201620152014 May 03, 2023 Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome Mar 28, 2023 Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days Mar 21, 2023 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results Jan 26, 2023 Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome Dec 19, 2022 Soleno Therapeutics Announces Financing Commitment for up to $60 Million Nov 09, 2022 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results Oct 03, 2022 Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome Sep 06, 2022 Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Aug 10, 2022 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results Jul 20, 2022 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
May 03, 2023 Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
Mar 28, 2023 Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days
Mar 21, 2023 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
Jan 26, 2023 Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome
Nov 09, 2022 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Oct 03, 2022 Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
Sep 06, 2022 Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug 10, 2022 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Jul 20, 2022 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome